New CAR-T combo targets tough myeloma early

NCT ID NCT06429150

First seen Apr 29, 2026 · Last updated May 10, 2026 · Updated 3 times

Summary

This early-phase trial tests a combination CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) in people with high-risk multiple myeloma or plasmacytoma. The goal is to see if this treatment is safe and can control the disease as a first-line therapy. About 20 participants will be enrolled, and researchers will also track how long the CAR-T cells last in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hematologist of the Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health

    RECRUITING

    Vladivostok, 690105, Russia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shenzhen Geno-immune Medical Institute

    RECRUITING

    Shenzhen, Guangdong, 518000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.